Read our Recent Headlines

August 17th Biotech Update

Up, down, up, down, and repeat. Yesterday was green so today is most likely to be red. While it is difficult to discern a trend in such a low volume,.

August 16th Biotech Update

The sector was pretty weak yesterday but remained in its range. While there is nothing to dissuade me from the summer chop, there are some warning signs. First, we are.

August 15th Biotech Update

A pretty weak open for the sector but again this is nothing more than low volume chop as I see it. Unless it breaks below 113 on the IBB and.

Bellus – David vs. Goliath Can BLU Deliver A Better Chronic Cough Drug Than Merck?

BELLUS Health (BLU.TO) (BLUSF) is a biopharmaceutical development company based in Quebec, Canada, its pipeline includes several partnered clinical-stage drug development programs, but the company’s lead drug candidate is BLU-5937.

August 13 Biotech Update

The chop continues and I suspect this week will be no different. There is not any news to start the week that would excite or disappoint, which means the previous.

August 10th Biotech Update

While yesterday ended up being quite positive for the sector (in general), I am still not going to read too much into it and would not be surprised to see.

August 9th Biotech Update

The chop continues. I just do not see anything definitive in either direction and am coming around to the belief that we are not going to see anything definitive soon..



Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!